Citation & Authors
Diabetes Metab Res Rev. 2025;41(5):e70070.
ABSTRACT · RESEARCH SUMMARY
Research summary
This Taiwanese National Health Insurance cohort found that SGLT2 inhibitor use in patients with diabetes and compensated cirrhosis was associated with lower risks of death (aHR 0.47; 95% CI 0.42–0.52), decompensation, hepatic failure, and hepatorenal syndrome. Longer cumulative treatment duration was also associated with lower risks. Treatment-selection and healthy-user bias remain important considerations in this observational study.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
